Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics Ltd. has announced that its previously unlisted options, issued under the ASX code CHMAAC, are now listed on the ASX under the code CHMO. This move allows option holders to trade these options on the ASX, aligning with the company’s recent non-renounceable pro-rata entitlement offer. The listing does not change the number or terms of the options, and the entitlement offer is set to close on 22 April 2025. This development is expected to enhance the liquidity and accessibility of the company’s options, potentially benefiting stakeholders by increasing market engagement and investment opportunities.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is a company operating in the biotechnology industry, focusing on developing innovative therapies. The company is primarily engaged in the research and development of advanced therapeutic solutions, with a market focus on leveraging novel technologies to address unmet medical needs.
Technical Sentiment Signal: Buy
Current Market Cap: A$9.07M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.